ReviewNeuroscience bulletin2026
Aberrant Gamma Oscillations in Parkinson's Disease.
Review in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder, with no definitive cure currently available. Within the basal ganglia-thalamocortical circuitry, PD is characterized by an imbalance between antikinetic beta oscillations (13-35 Hz) and prokinetic gamma oscillations (60-90 Hz). While the pathological features and mechanisms underlying abnormal beta activity have been extensively studied, alterations in gamma oscillations remain much less well understood. Emerging evidence indicates that different forms of gamma activity are disrupted in PD and associated with symptoms such as dyskinesia, gait impairment, and rapid eye movement (REM) sleep behavior disorder. This review summarizes current clinical and preclinical evidence of aberrant gamma oscillations in PD, discusses underlying mechanisms including parvalbumin interneuron dysfunction, basal ganglia circuit imbalance, and impaired neurovascular coupling, and summarizes how current therapeutic approaches for PD modulate gamma activity and potentially influence clinical outcomes.
Indexed as
Identifiers
42678655What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.